Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients

URN to cite this document:: urn:nbn:de:bvb:355-epub-785240
DOI to cite this document:: 10.5283/epub.78524

Scheiter, Alexander

; Mellin, Simon ; Keil, Felix

; Meier, Johannes ; Heudobler, Daniel

; Brummer, Christina ; Einhell, Sabine

; Zwicker, Benjamin ; Wutzlhofer, Elena ; Hierl, Frederik ; Klemm, Sophie ; Lüftl, Elena ; Schneider, Tom ; Perl, Markus ; Klier-Richter, Margit ; Immel, Alexander ; Kaltofen, Till

; Grube, Matthias ; Bumes, Elisabeth

; Seitz, Stephan ; Schulz, Christian

; Haferkamp, Sebastian

; Drexler, Konstantin

; Troeger, Anja ; Steger, Felix ; Schlosser-Hupf, Sophie ; Tews, Hauke Christian ; Kandulski, Arne

; Wohlfart, Kristina ; Erber, Ramona

; Schönbuchner, Ines ; Lessel, Davor

; Schnabel, Marco J. ; Sedlmeier, Anja M.

; Klinkhammer-Schalke, Monika ; Maurer, Julia

; Calvisi, Diego F.

; Pukrop, Tobias

; Kaiser, Ulrich

; Hirsch, Daniela ; Dietmaier, Wolfgang ; Evert, Matthias ; Lüke, Florian

; Utpatel, Kirsten

License: Creative Commons Attribution 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 29 Jan 2026 05:38

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Abstract

Background
Molecular tumor boards (MTBs) are essential for selecting therapies for patients with rare and advanced cancers. We hypothesized that integrating biomarkers beyond targeted DNA/RNA next-generation sequencing (NGS) could increase actionable findings. Human epidermal growth factor receptor 2 (HER2)-low status has emerged as a critical biomarker in breast cancer, with potential relevance across other tumor types. Homologous recombination deficiency (HRD) is pivotal for the application of Poly(ADP-Ribose)-Polymerase (PARP) inhibitors in ovarian and breast cancer, although its role in other malignancies remains unclear. Antibody–drug conjugates (ADCs) are expanding precision oncology, with promising biomarkers like Trop-2, Nectin-4, and folate receptor alpha (FRα) showing potential across multiple tumor entities.
Methods
Tumors were analyzed using the TSO500® panel, enabling tumor mutational burden (TMB) readout. HER2 status was assessed via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), alongside antibody–drug conjugate (ADC) IHC, microsatellite instability (MSI) polymerase chain reaction (PCR), mismatch repair (MMR) IHC, programmed death-ligand 1 (PD-L1) IHC, and HRD analysis. Cases were discussed weekly, and outcomes were systematically tracked. Data analysis evaluated the benefit of additional biomarker assessments.
Results
Among 658 patients, 329 received therapy recommendations, 182 based on supplementary biomarker analyses. One hundred recommendations were implemented, with 37% attributed to supplementary diagnostics. Among 64 response-evaluable patients, the clinical benefit rate (complete response + partial response + stable disease) was 45.3%. HER2-low status notably expanded targeted therapy options across tumor types, with similar implementation rates for HER2-low and HER2-amplified tumors. HRD analysis refined stratification in tumors with mutations in homologous recombination repair (HRR) genes beyond BRCA1/2, including PALB2, ATM, and CHEK2. ADC IHC supported 20 recommendations and two therapy implementations.
Conclusions
The integration of additional biomarker assessments into MTB workflows enhances precision oncology by expanding the pool of patients eligible for targeted therapies.

Owner only: item control page

Download Statistics

Altmetric

Alternative Statistics (altmetrics)

More literature (via CORE)

Details

Preview

Export bibliographical data

Abstract

Abstract

Download Statistics

Downloads

Alternative Statistics (altmetrics)

More literature (via CORE)

University Library